来迪派韦/索磷布韦8周方案治疗慢性丙型肝炎的真实世界疗效
基于德国丙型肝炎登记处2404例患者的真实世界队列,比较来迪派韦/索磷布韦8周与12周方案治疗慢性HCV感染的效果。8周组ITTI SVR12为85.1%(824/968),12周组为85.5%(1210/1415);符合SmPC标准者PP人群SVR12达98.7%(739/749)。结论认为8周方案在符合条件的患者中可获得与12周相当的治愈率。
要点
- 8周组ITTI SVR12为85.1%(824/968),12周组为85.5%(1210/1415)。
- 符合SmPC标准者PP人群SVR12为98.7%(739/749)。
- 8周组肝硬化患者PP人群复发率为9.5%(2/21)。
核心结论
- 在真实世界条件下,接受8周来迪派韦/索磷布韦治疗的合格患者中高比例获得SVR12。
- 不符合SmPC选择标准的患者复发更频繁。
- 在主要为德国私人执业医师治疗的大型真实世界队列中,基因1型HCV感染患者8周短程治疗与12周治疗获得等效治愈率。
研究设计与样本
- 德国丙型肝炎登记处是一项大型全国性真实世界队列,分析慢性HCV抗病毒治疗的有效性与安全性。
- 本数据集基于2404例患者,索磷布韦/来迪派韦(不含利巴韦林)8周或12周治疗于2015年9月30日或之前启动。
主要发现
- 总体安全性人群(ITT1)84.6%(2034/2404)和符合方案(PP)人群98.2%(2029/2066)获得SVR12。
- 8周组ITTI SVR12为85.1%(824/968),PP人群为98.3%(821/835);12周组ITTI SVR12为85.5%(1210/1415),PP人群为98.1%(1208/1231)。
- 按SmPC标准治疗的患者中,PP人群98.7%(739/749)获得SVR12。
- 8周治疗的肝硬化患者PP人群复发率为9.5%(2/21)。
关键数值与推荐
- 根据SmPC,8周治疗可考虑用于初治无肝硬化基因1型患者。
- ION-3研究中,8周来迪派韦/索磷布韦在初治无肝硬化基因1型患者中不劣于12周。
临床怎么用
- 作者认为,在基因1型HCV感染患者中可推荐短程(8周)治疗,这将大幅降低治疗费用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Ledipasvir/sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV). In the ION-3 study, 8 weeks of LDV/SOF was non-inferior to 12 weeks in previously untreated genotype 1 (GT1) patients without cirrhosis. According to the Summary of Product Characteristics (SmPC), 8-week treatment may be considered in naïve non-cirrhotic GT1-patients. However, there are only limited data on the effectiveness of an 8-week regimen of LDV/SOF under real-world conditions. The aim of the present study was to characterise patients receiving 8 weeks of LDV/SOF compared to those receiving 12 weeks of LDV/SOF, and to describe therapeutic outcomes in routine clinical practice. METHODS: The German Hepatitis C-Registry is a large national real-world cohort that analyses effectiveness and safety of antiviral therapies in chronic HCV. This data set is based on 2,404 patients. Treatment with SOF/LDV (without RBV) for 8 or 12 weeks was initiated on or before September 30, 2015. RESULTS: Overall, 84.6% (2,034/2,404) of the safety population (intention-to-treat-1 [ITT1]) and 98.2% (2,029/2,066) of the per protocol (PP) population achieved sustained virological response at week 12 (SVR12). In the 8-week group, 85.1% (824/968) of ITT1 and 98.3% (821/835) of PP patients achieved SVR12, while in the 12-week group, 85.5% (1,210/1,415) of ITT1, and 98.1% (1,208/1,231) of PP patients achieved SVR12. When treated according to the SmPC, 98.7% (739/749) of the patients achieved SVR12 (PP). Relapse was observed in 9.5% (2/21) of cirrhotic patients treated for 8 weeks (PP). CONCLUSIONS: Under real-world conditions a high proportion of eligible patients receiving 8-week LDV/SOF treatment achieved SVR12. Relapse occurred more frequently in patients who did not meet the selection criteria according to the SmPC. LAY SUMMARY: In a large real-world cohort of patients mainly treated by physicians in private practice in Germany, shorter HCV treatment (8-week) resulted in equivalent cure rates to 12-week treatment in genotype 1 HCV-infected patients. Thus, shorter treatment can be recommended in these patients which would substantially reduce costs of therapy. Clinical Trial number: DRKS00009717 (German Clinical Trials Register, DRKS).
引用
- Buggisch P, Vermehren J, Mauss S, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol. 2017. PMID: 29133244. doi:10.1016/j.jhep.2017.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。